DENVER, Feb. 17, 2005 (PRIMEZONE) -- Medical International Technology, Inc. (OTCBB:MDIR) (http://www.mitcanada.ca) ("MIT") is pleased to announce it has retained the services of AGORA Investor Relations ("AGORA") (http://www.agoracom.com) to provide investor relations, communications and marketing services.
The objective of this agreement is to create effective communication between MIT, its shareholders and the investment community through AGORA's powerful Internet based investor relations system. A customized and monitored IR Hub will allow both MIT and AGORA to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications.
MIT President and CEO, Karim Menassa, stated, "With the Japanese Ministry of Agriculture, Fishery and Forestry officially approving our AGRO-JET injectors for marketing and sale in Japan in late 2004, MIT is now back to focus on sales and marketing in 2005 and beyond. As such, it is now necessary to commence an active investor relations program that supports our anticipated corporate developments."
Shareholders can access the MIT IR Hub at http://www.agoracom.com and selecting the "Medical International" Hub, located under "US Stocks". The Hub also contains a complete broker fact sheet, company profile and executive address by Mr. Menassa.
About AGORA Investor Relations Corp. http://www.agoracom.com http://www.AgoraIR.com
AGORA Investor Relations Corp. (AGORA) is North America's leading outsourced IR firm for small-cap companies. AGORA's exclusive IR Hub delivers two-way investor relations and communications that provides 100% transparency, accessibility and near real-time communications for all shareholders and interested parties.
AGORA has represented over 40 small-cap companies since 1997 and is the exclusive provider of all content to the AOL Small Cap Channel.
About Medical International Technology, Inc. http://www.mitcanada.ca
MIT CANADA, with offices in Montreal, is a subsidiary of Denver, Colorado-based Medical International Technology, Inc. (MIT USA), which specializes in the development, production, marketing and sale of needle-free injectors both for humans and animals, for individual and mass vaccinations.
This press release contains certain "forward-looking" statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995 that involves a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the Company. They include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors that may be identified from time to time in the Company's public announcements.